Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Forte Biosciences, Inc.NASDAQ: FBRX
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments remains negative
Q1 FY2026 short-term investments was $0, compared with $0 a year earlier.
Context
- Short-term investments amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Short-term investments increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 36.12M | +43.5% |
| FY2023 | 2023-12-31 | 25.16M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Short-term Investments vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term investments is compared through growth and share of total assets rather than absolute size.
- Short-term investments amounts to 0.0% of total assets for FBRX, versus a peer median of 54.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $203.07M USD | -4.6% | -9.1% | 54.6% | |
| Mar 2026 | $135.25M USD | -30.8% | -25.2% | 47.5% | |
| Mar 2026 | $129.55M USD | -59.1% | -30.2% | 54.0% | |
| Mar 2026 | $112.56M USD | -1.2% | +47.3% | 77.9% | |
| Mar 2026 | $90.15M USD | +66.5% | — | 57.7% | |
| Mar 2026 | $37.51M USD | -32.8% | -22.8% | 76.3% | |
| Mar 2026 | CHF 14.52M CHF | -70.7% | -59.9% | 16.6% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
ACTUActuate Therapeutics Inc | Mar 2026 | $0 USD | — | — | 0.0% |
| Peer median (excluding FBRX) | — | -30.8% | -24.0% | 54.0% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.